Clinical Trials Logo

HER2+ Breast Cancer clinical trials

View clinical trials related to HER2+ Breast Cancer.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT05931042 Completed - HER2+ Breast Cancer Clinical Trials

Neoadjuvant Therapy With Trastuzumab and Chemotherapy and the Resultant Pathologic Complete Response Observed in HER2 Positive Breast Cancer;a Systematic Review

Start date: June 1, 2023
Phase:
Study type: Observational

The goal of this systematic review is to assess the effectiveness of neoadjuvant chemotherapy and Trastuzumab in achieving pathological complete response (pCR) in patients with HER2-positive breast cancer. The main questions it aims to answer are: - What is the overall rate of pathological complete response (pCR) in HER2-positive breast cancer patients treated with neoadjuvant chemotherapy and Trastuzumab? - Are there any variations in the definition of pCR among the included trials? Participants in the selected clinical trials were HER2-positive breast cancer patients with non-metastatic operable, locally advanced, or inflammatory breast cancer. The main tasks participants were asked to do and the treatments they received are as follows: - Undergo neoadjuvant chemotherapy: Participants received chemotherapy treatment before their primary surgery. - Receive Trastuzumab: Participants were administered Trastuzumab, a targeted therapy for HER2-positive breast cancer. Researchers would compare the group of participants receiving neoadjuvant chemotherapy and Trastuzumab to other groups, if present, to see if there are differences in the rates of pathological complete response (pCR) or other effects.

NCT ID: NCT01598077 Completed - Clinical trials for Esophageal Squamous Cell Carcinoma

A Phase I Study of LJM716 in Squamous Cell Carcinoma of Head and Neck, or HER2+ Breast Cancer or Gastric Cancer

Start date: July 2012
Phase: Phase 1
Study type: Interventional

This primary purpose of this study is to estimate the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE) and preferred dosing schedule of LJM716 given by IV infusion in adult patients with squamous cell carcinoma of head and neck, or esophagus, or HER2 overexpressing metastatic breast cancer or gastric cancer